| 查看: 1438 | 回复: 4 | |||
zlwcw木虫 (著名写手)
|
[交流]
【讨论】2010 制药公司大裁员意味着 中国的就业几率会大幅增加 已有1人参与
|
|
http://blog.pharmexec.com/2010/1 ... ffs-for-big-pharma/ 2010: A Year of Big Layoffs for Big Pharma By Jennifer Ringler | Published: October 19, 2010 What are the factors that are contributing to the layoffs that have taken place at virtually all the Big Pharma companies this year? According to the newly released Job-Cut Announcement Report from outplacement consultancy firm Challenger, Gray & Christmas, pharma has cut more than 6,000 jobs in September alone, and more than 43,000 so far this year. Which companies have contributed to this staggering number, and what are the underlying causes of job losses in the industry? Most recently, Sanofi-Aventis announced its plans to eliminate 1,700 jobs in its US pharma business—about 25 percent of the company’s US pharma workers. The majority of jobs lost will be sales positions, and a small number of administrative jobs will disappear as well. Before that, in September, Roche announced its “Operational Excellence Initiative,” which—while partly intended to analyze and restructure different segments of the company to maximize productivity and ROI—ultimately amounted to job cuts in an effort to “set the right priorities to ensure a successful future,” according to a statement released by Roche. In May, Pfizer announced 6,000 layoffs that it said was part of “manufacturing reorganization” following its 2009 Wyeth acquisition. Possibly part of its plan to remain on track for its targeted cost reduction of $4 to $5 billion by the end of 2012, Pfizer has gone from nearly 114,000 employees internationally in Q 1 2010 to around 33,000 as of May of this year, according to a story on DailyFinance.com. Following its 2009 acquisition of Schering-Plough, Merck began making cuts in February. The post-merger cuts would be a way to “eliminate some of the duplication,” according to a statement made in January by Merck CEO Dick Clark. “We have taken the best from both companies, from a process standpoint and a people standpoint,” he said. And at the start of the year, way back in January, AstraZeneca announced its plan to cut around 8,000 jobs—four percent of its total workforce—over the next four years. As it does for so many Big Pharma players, the patent cliff lies at the heart of the issue. AstraZeneca products scheduled to lose patent protection this year are Armidex, a breast cancer therapy; and Pulmicort Respules, an asthma treatment. Part of the trouble for drug manufacturers is the looming patent expiration dates and impending generics competition. Three of Sanofi’s top products—anticlotting medicines Lovenox and Plavix and cancer drug Taxotere—have or will soon have new generic competition, jeopardizing nearly $10 billion of the company’s $40 billion in annual sales, according to a story on Yahoo! Finance. There are several other factors that are contributing to the layoffs trend: • Structural transformations in the marketplace, focused on the declining relevance of a large sales force in an era of managed care as well as more targeted high-yield approaches to drug development that require less dedicated staff for R&D operations. • Redeployment of assets in line with globalization and the ability to dig deep in untapped growth markets. Job losses in the US and Europe mean that more workers can be hired in countries like China—where, for example, turnover among sales forces is quite high and needs frequent replenishment. • Advances in information technology that improve productivity for a smaller workforce. Information is not only a strategic asset; it is a labor-saving instrument to replace back-office functions and support more automation in manufacturing. • The high cost of producing biologicals drugs are forcing companies to be more selective in where they manufacture, with fewer plants staffed by fewer people with more skills. While such redistribution of assets and focus on greater ROI can be positive for a company as a whole, it can have negative effects on individual workers. In an industry that was once thought to be immune to layoffs, the dynamic can change if workers become wary of job loss, shifting toward a culture of bureaucratic self-preservation that may not always be in line with the importance of fostering entrepreurialism and prudent risk taking. |
回复此楼» 猜你喜欢
211高校2026年入学博士名额
已经有16人回复
-
海勃原辅料助力银屑病一线外用制剂开发
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有133人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
-
二乙烯基砜的合成路径
已经有4人回复
-
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
-
求助！求美国食品化学药典内容：FCC13【低聚果糖专论】
已经有0人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
消耗微量API，便可预测早期研发阶段的HME工艺可行性
已经有0人回复
-
反应液中苯酐除去
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 中北大学化学工程（专硕）到底怎么样？就业形势如何？
已经有20人回复
- 有机化学就业咨询
已经有8人回复
- 关于应用化学（偏向材料方向）博士的就业
已经有11人回复
- FDA对于仿制药的审评策略
已经有70人回复
- 请问仿制药研究中需要买原研制剂，买出厂后几个月的合适
已经有6人回复
- 仿制药改规格！
已经有23人回复
- 化学制药厂新型设备交流
已经有28人回复
- 失效模式和效果分析(FMEA)在制药行业的应用
已经有55人回复
- 《制药经理人》（Pharm Exec)对全球最大的制药公司前50强的排位
已经有76人回复
- 向大家请教，苏州有什么好点的化学和制药类企业？？？
已经有4人回复
- 【交流】中检所无对照品，制药厂怎么执行中国药典2010版？
已经有29人回复
sdlj82
金虫 (正式写手)
每年都拖平均工资的后腿
- 应助: 10 (幼儿园)
- 金币: 1190.6
- 帖子: 394
- 在线: 86.3小时
- 虫号: 83032
- 注册: 2005-07-28
- 性别: GG
- 专业: 中药制剂
2楼2010-10-30 09:32:44
3楼2010-10-30 16:40:35
4楼2010-10-30 19:56:12
liao_xinglong
铁杆木虫 (正式写手)
- 应助: 15 (小学生)
- 金币: 7243.3
- 散金: 3
- 帖子: 803
- 在线: 654.3小时
- 虫号: 246016
- 注册: 2006-04-29
- 性别: GG
- 专业: 有机合成
5楼2010-11-01 10:49:27
